\
&
Contact us
This was 1 year ago
LocationVirtual
ProgrammesGetting ready for the opening of the calls for 2025 also implies finding (potential) partners. To facilitate this, you can participate in a brokerage event with pre-arranged online face-to-face meetings. For cluster4, 3 events are being set up: for digital topics, for space topics and for industry topics.
Detailed information and registration is available on the websites of the brokerages (see below). The agenda is as simple and effective as possible: full days (from 08:00 until 19:00 CET) with available timeslots for bilateral meetings. If it is new to you, you might want to read up on how such a brokerage works.
This brokerage event complements the official and EC-organised Cluster 4 Info Day.
These events are open to representatives of companies, universities and research institutes interested in sharing new project ideas and finding collaboration partners. More than 1500 researchers, innovators, entrepreneurs, industry representatives, young people and policy makers are expected to attend.
The calendar of the upcoming Info Days and brokerage events on Cluster 4, includes:
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.